News

Vaxcyte Launches Exciting Phase 2 Study of VAX-31 Vaccine

Vaxcyte Launches Exciting Phase 2 Study of VAX-31 Vaccine

Phase 2 Study of VAX-31 Shows Promise for Infant Protection

Vaxcyte, Inc. (NASDAQ: PCVX), a trailblazer in vaccine innovation, has announced a significant advancement in its commitment to combating invasive pneumococcal disease (IPD) in infants. The company has initiated a Phase 2 clinical study focused on VAX-31, a groundbreaking candidate intended to protect infants from potentially life-threatening infections caused by Streptococcus pneumoniae.

What is VAX-31?

VAX-31 is a 31-valent pneumococcal conjugate vaccine designed specifically for infants. This innovative vaccine aims to cover around 94% of invasive pneumococcal disease and 93% of acute otitis media in U.S. children under five. By doing so, it provides broader protection against both current circulating strains and historically prevalent serotypes typically found in existing standard-of-care vaccines.

Study Details and Expectations

In early 2026, Vaxcyte expects to present the topline data from the primary immunization series of the VAX-31 study, reflecting its safety, tolerability, and immunogenicity in a three-dose schedule. This study has already begun dosing its first participants—marking an exciting milestone in Vaxcyte’s ongoing clinical development of pneumococcal vaccines.

Stages of Evaluation

This Phase 2 study consists of two stages: the first involves approximately 48 infants and evaluates the safety and tolerability of VAX-31 at varying doses compared to the existing Prevnar 20 vaccine. Successful participants from this stage will transition to Stage 2, which includes a broader cohort of around 750 infants.

Immunogenicity Focus

The study places a robust emphasis on immunogenicity—the ability of the vaccine to provoke an immune response. Key immunogenicity endpoints will assess the serotype-specific IgG responses, essential for establishing the effectiveness of VAX-31 in providing adequate protection against pneumococcal infections.

Addressing Pneumococcal Disease Concerns

Pneumococcal disease is recognized as a leading cause of severe illness among young children worldwide. As the primary cause of vaccine-preventable deaths in children under five, it highlights the critical need for broader-spectrum vaccines like VAX-31. The existing vaccines do not adequately cover all serotypes responsible for severe infections, creating a gap in protection that VAX-31 aims to fill.

Vaxcyte’s Vaccine Development Journey

Vaxcyte is not only developing VAX-31 but is also actively working on VAX-24, another promising vaccine candidate aimed at further expanding coverage for infants. Their innovative approach to vaccine development utilizes advanced synthetic techniques, enabling the efficient creation of high-fidelity vaccines capable of responding to complex bacterial infections.

Company Vision and Commitment

Through its meticulous research and development, Vaxcyte aims to improve vaccination outcomes significantly and tackle the public health challenges posed by antibiotic-resistant strains of bacteria. As part of its broader mission, the company is committed to delivering vaccines that offer enhanced protection and efficacy for vulnerable populations, particularly infants and young children.

Conclusion and Future Outlook

With the VAX-31 study underway, Vaxcyte is positioning itself as a leader in vaccine innovation. The expected data releases in the upcoming years could provide crucial insights into the effectiveness of VAX-31, opening up new possibilities for preventing invasive pneumococcal disease in infants. Vaxcyte's pioneering efforts demonstrate a dedication not only to developing effective vaccines but also to ensuring that these life-saving interventions reach those who need them the most.

Frequently Asked Questions

What is VAX-31?

VAX-31 is a 31-valent pneumococcal conjugate vaccine designed to protect infants from invasive pneumococcal disease.

What are the primary goals of the Phase 2 study?

The main goals include assessing safety, tolerability, and immunogenicity of VAX-31 in healthy infants.

When can we expect results from the study?

Topline results from the primary immunization series are expected in mid-2026, followed by booster dose data about nine months later.

Why is this study significant?

The study is crucial as it aims to provide broader protection against pneumococcal disease, which remains a serious health threat for young children.

How does VAX-31 compare to existing vaccines?

VAX-31 is designed to cover more serotypes, thereby providing greater protection compared to current vaccination options.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 27

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 46

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
SeoulTech's Liver Chip Makes Toxicity Testing Practical

Updated Category News Views 32

A Lab Tool Finally Built for the Messy Part Thousands of everyday chemicals are floating around commerce with thin toxicity records, and that is a lousy way to run a modern economy. Seoul National University of Science and Technology researchers have put forward a modular liver-on-a-chip platform aimed squarely at that gap: making environmental chemical testing more...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 111

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 93

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Starbucks Workers Unite in Major Strike Action Ahead of Holidays

Updated Category News Views 645

Starbucks Workers Prepare for Significant Strike Starbucks (NASDAQ: SBUX) workers, represented by a union encompassing more than 10,000 individuals, have announced plans for a strike in major cities like Los Angeles, Chicago, and Seattle. This strike is set to commence on Friday and is expected to last through the busy Christmas season. Union's Demands for Better...

Continue Reading
Discover Häagen-Dazs® Summer Blueberry Collection Now!

Updated Category News Views 140

Häagen-Dazs® Shops Launches Delicious Summer Blueberry Collection The summer season is here, and Häagen-Dazs® Shops embraces it with their enticing Summer Blueberry Collection. This delightful selection is all about providing a refreshing and revitalizing experience for ice cream lovers. With an exquisite range of flavors, including the brand's first-ever oat...

Continue Reading
Innovative Beef Supply Chain By Rancher's Sustainable Angus Alliance

Updated Category News Views 240

Transforming the Beef Supply Chain for Sustainability The Rancher's Sustainable Angus Alliance (RSAA) is actively engaging with beef retail partners who are committed to delivering top-notch Angus beef while emphasizing animal welfare and environmental responsibility. Founded by a group of visionary seedstock ranchers, RSAA aims to connect consumers with the rich heritage...

Continue Reading
Emerging Trends and Growth in Global Glucose Testing Market

Updated Category News Views 131

Overview of the Global Point-of-Care Glucose Testing Market The Point-of-Care Glucose Testing Market is experiencing significant growth, fueled by increasing rates of diabetes globally and a shift towards more accessible healthcare solutions. As patients and healthcare providers seek easier and more accurate ways to manage diabetes, this market is expected to thrive,...

Continue Reading
Artesian Resources Corporation Celebrates Strong Growth in 2025

Updated Category News Views 182

Artesian Resources Corporation's Impressive Performance Artesian Resources Corporation (NASDAQ: ARTNA), a distinguished provider of water and wastewater services on the Delmarva Peninsula, has recently disclosed its remarkable financial performance for the third quarter and year-to-date of 2025. The reports reveal significant increases in both revenue and net income,...

Continue Reading